Investor Sanofi
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Sanofi . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-04-29 13G/A 8,345,387
2025-04-29 13G 8,345,387
2024-08-13 13G/A MGTX / MeiraGTx Holdings plc 4,697,737 12,197,737
2024-05-31 13G INBX / Inhibrx Biosciences, Inc. 1,157,926
2023-11-06 13G MGTX / MeiraGTx Holdings plc 4,697,737
2022-02-08 13G ICVX / Icosavax, Inc. 3,155,169
2021-08-12 13D TBIO / Telesis Bio, Inc. 4,884,434 3,684,434
2021-03-31 13G LVTX / LAVA Therapeutics N.V. 1,919,455
2021-02-11 13G RVMD / Revolution Medicines, Inc. 3,363,050
2021-02-04 13G TBIO / Telesis Bio, Inc. 4,884,434
2020-06-17 13D/A REGN / Regeneron Pharmaceuticals, Inc. 23,221,451 279,766
2020-05-29 13D/A REGN / Regeneron Pharmaceuticals, Inc. 23,350,365 23,221,451
2020-02-10 13G/A RGLS / Regulus Therapeutics Inc. 8,706,526 0
2020-02-10 13G/A COGT / Cogent Biosciences, Inc. 1,773,481 842,048
2019-12-09 13D/A REGN / Regeneron Pharmaceuticals, Inc. 23,880,537 23,350,365
2019-07-29 13G FULC / Fulcrum Therapeutics, Inc. 558,035
2019-05-03 13G/A ALNY / Alnylam Pharmaceuticals, Inc. 10,554,134 0
2019-02-15 13G/A US62857M1053 / MyoKardia, Inc. 4,168,899 0
2019-02-12 13G/A SCYX / SCYNEXIS, Inc. 1,548,751 0
2019-02-11 13G COGT / Cogent Biosciences, Inc. 1,773,481
2019-02-11 13G/A US62857M1053 / MyoKardia, Inc. 4,018,899 4,168,899
2019-02-11 13G/A VYGR / Voyager Therapeutics, Inc. 2,477,941 0
2018-06-19 13D/A ABYLY / Ablynx NV 74,567,835 78,001,392
2018-05-25 13D ABYLY / Ablynx NV 74,567,835
2018-02-13 13G/A SCYX / SCYNEXIS, Inc. 1,548,751
2018-02-13 13G/A US62857M1053 / MyoKardia, Inc. 3,668,899 4,018,899
2018-02-13 13G/A ALNY / Alnylam Pharmaceuticals, Inc. 10,256,633 10,554,134
2018-02-13 13G/A RGLS / Regulus Therapeutics Inc. 8,706,526
2018-01-09 13D/A REGN / Regeneron Pharmaceuticals, Inc. 23,505,694 23,880,537
2017-02-09 13G/A US62857M1053 / MyoKardia, Inc. 3,218,899 3,668,899
2017-01-31 13D/A REGN / Regeneron Pharmaceuticals, Inc. 23,108,570 23,505,694
2016-02-12 13G/A ALNY / Alnylam Pharmaceuticals, Inc. 10,256,633
2016-02-12 13G US62857M1053 / MyoKardia, Inc. 3,218,899
2016-02-12 13G VYGR / Voyager Therapeutics, Inc. 2,477,941
2015-12-29 13D/A REGN / Regeneron Pharmaceuticals, Inc. 23,108,570
2015-02-13 13G/A MACK / Merrimack Pharmaceuticals, Inc. 3,074,718
2015-02-13 13G/A SCYX / SCYNEXIS, Inc. 1,677,057
2015-02-02 13G/A ALNY / Alnylam Pharmaceuticals, Inc. 10,051,603
2014-10-17 13D/A REGN / Regeneron Pharmaceuticals, Inc. 22,535,558
2014-08-01 13G IMDZ / Immune Design Corp. 917,429
2014-07-31 13G IMDZ / Immune Design Corp. 917,429
2014-07-31 13D/A REGN / Regeneron Pharmaceuticals, Inc. 22,204,841
2014-07-09 13D/A REGN / Regeneron Pharmaceuticals, Inc. 21,405,741
2014-07-01 13D/A REGN / Regeneron Pharmaceuticals, Inc. 20,258,841
2014-05-09 13G SCYX / SCYNEXIS, Inc. 1,677,057
2014-04-09 13D/A REGN / Regeneron Pharmaceuticals, Inc. 20,018,090
2014-04-08 13D/A REGN / Regeneron Pharmaceuticals, Inc. 20,018,090
2014-03-27 13D/A REGN / Regeneron Pharmaceuticals, Inc. 19,404,200
2014-03-14 13D/A REGN / Regeneron Pharmaceuticals, Inc. 17,994,836
2014-03-05 13G ALNY / Alnylam Pharmaceuticals, Inc. 8,766,338
2014-03-05 13D/A REGN / Regeneron Pharmaceuticals, Inc. 17,001,214
2014-02-05 13G/A RGLS / Regulus Therapeutics Inc. 5,053,779
2014-01-29 13D/A REGN / Regeneron Pharmaceuticals, Inc. 15,974,873
2014-01-14 13D REGN / Regeneron Pharmaceuticals, Inc.
2012-10-09 13G RGLS / Regulus Therapeutics Inc. 3,749,999
2012-04-02 13G MACK / Merrimack Pharmaceuticals, Inc. 5,217,391